Galmed to add open label part to armor study; first read-out expected in q4 2021

Tel aviv, israel, dec. 17, 2020 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its armor phase 3...

GLMD Ratings Summary

GLMD Quant Ranking